PerkinElmer Launches EUROIMMUN ELISA for Detection of Aspergillus Infections

August 5, 2019

New assay provides in vitro determination of galactomannoprotein in immunocompromised patients

WALTHAM, Mass. – August 5, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the new EUROIMMUN *Aspergillus* Antigen ELISA.* The enzyme-linked immunosorbent assay is specifically designed to detect the Aspergillus antigen galactomannoprotein and assist in distinguishing invasive aspergillosis (IA).

Aspergillosis is an infection disease caused by *Aspergillus*, a common mold whose spores are spread indoors and outdoors through the air humans breathe. Inhalation of the spores is typically not harmful, but infections can occur in those with a weakened immune system, such as patients undergoing chemotherapy or bone marrow transplants.

IA, the most life-threatening form of aspergillus infection, commonly affects the lungs of immunocompromised patients, but pathogens often spread throughout the body to the central nervous system, eyes, heart and kidneys. Cases of IA have a high mortality rate, ranging up to 90%, especially if the central nervous system is impacted.[1]

"Timely detection and diagnosis of this dangerous infection is critical to ensuring proper treatment and preventing fatalities," said Dr. Wolfgang Schlumberger, Ph.D., CEO of EUROIMMUN, a PerkinElmer company. "Clinical studies have shown that the EUROIMMUN Aspergillus Antigen ELISA delivers high sensitivity and specificity in detecting galactomannoprotein.[2] And, when processed using the automated EUROIMMUN Analyzer system, our ELISA seamlessly integrates into a laboratory workflow for faster detection of *Aspergillus* infections at an earlier stage."

Detection of *Aspergillus* antigen is included in the guidelines of the Infectious Diseases Society of America (IDSA), the European Organization for Research and Treatment of Cancer (EORTC) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) as a criterion of a "probable" IA infection.

EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing. Its expertise and capabilities extend across immunology, cell biology, histology, biochemistry and molecular biology.

For more information about the EUROIMMUN *Aspergillus* Antigen ELISA, click here.

**PerkinElmer's EUROIMMUN Aspergillus Antigen ELISA is available for research use only and not for use in diagnostics in the United States. Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.*

About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.8 billion in 2018, serves customers in more than 180 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contact:
Sara LaFauci
sara.lafauci@perkinelmer.com
+1-781-663-6946

---

[1] M. Kousha, R. Tadi, A.O. Soubani. (2011). Pulmonary aspergillosis: a clinical review. European Respiratory Society.
[2] Dichtl, K. et al. (2019). Evaluation of a novel *Aspergillus* Antigen ELISA. Journal of Clinical Microbiology.